Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer
…, C Shimizu, A Hirakawa, K Harano… - International journal of …, 2013 - Springer
Background The long-term outcomes and risk factors of paclitaxel-induced peripheral
neuropathy (PIPN) have not yet been fully elucidated. Methods We identified 219 breast cancer …
neuropathy (PIPN) have not yet been fully elucidated. Methods We identified 219 breast cancer …
Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group
K Harano, A Hirakawa, M Yunokawa… - International journal of …, 2016 - Springer
Background Uterine carcinosarcomas (UCSs) are rare and aggressive tumors. The
prognostic factors are not sufficiently known. Methods We performed a multi-institutional, …
prognostic factors are not sufficiently known. Methods We performed a multi-institutional, …
TAS-116 (pimitespib), an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: An open-label, dose-finding …
…, D Kotani, Y Kuboki, H Taniguchi, K Harano… - Clinical Cancer …, 2021 - AACR
Purpose: This is a phase Ib trial of TAS-116, an oral HSP90 inhibitor, plus nivolumab for
colorectal cancer and other solid tumors. Patients and Methods: Enrolled patients received TAS-…
colorectal cancer and other solid tumors. Patients and Methods: Enrolled patients received TAS-…
Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0)
…, H Bando, Y Fujimoto, S Fukuoka, K Harano… - Cancer …, 2018 - Wiley Online Library
In Japan, the social (medical) health‐care system is on the way to being developed to advance
personalized medicine through the implementation of cancer genomic medicine, known …
personalized medicine through the implementation of cancer genomic medicine, known …
Dry sliding friction and Wear behavior of thermoplastic polyurethane against abrasive paper
Thermoplastic polyurethane (TPU) is attractive as the outer sole of running shoes because
of its excellent mechanical properties and ease of processing. This study investigated the …
of its excellent mechanical properties and ease of processing. This study investigated the …
[HTML][HTML] Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype
In patients with triple-negative breast cancer (TNBC), tumor-infiltrating lymphocytes (TILs) are
associated with improved survival. Lehmann et al. identified 4 molecular subtypes of TNBC …
associated with improved survival. Lehmann et al. identified 4 molecular subtypes of TNBC …
[HTML][HTML] MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer
Inflammatory breast cancer is the most aggressive form of breast cancer. Identifying new
biomarkers to be used as therapeutic targets is in urgent need. Messenger RNA expression …
biomarkers to be used as therapeutic targets is in urgent need. Messenger RNA expression …
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826
…, Y Aoki, H Itamochi, M Takekuma, K Harano… - Cancer …, 2022 - Wiley Online Library
Pembrolizumab plus chemotherapy with or without bevacizumab demonstrated prolonged
progression‐free survival (PFS) and overall survival (OS) versus chemotherapy in patients …
progression‐free survival (PFS) and overall survival (OS) versus chemotherapy in patients …
[HTML][HTML] Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and …
K Harano, F Terauchi, N Katsumata, F Takahashi… - Annals of …, 2014 - Elsevier
Background Dose-dense weekly paclitaxel (Taxol) and carboplatin (dd-TC) improved
survival compared with conventional tri-weekly paclitaxel and carboplatin (c-TC) as a first-line …
survival compared with conventional tri-weekly paclitaxel and carboplatin (c-TC) as a first-line …
Changes in triple-negative breast cancer molecular subtypes in patients without pathologic complete response after neoadjuvant systemic chemotherapy
H Masuda, K Harano, S Miura, Y Wang… - JCO Precision …, 2022 - ascopubs.org
PURPOSE Lehmann et al have identified four molecular subtypes of triple-negative breast
cancer (TNBC)—basal-like (BL) 1, BL2, mesenchymal (M), and luminal androgen receptor—…
cancer (TNBC)—basal-like (BL) 1, BL2, mesenchymal (M), and luminal androgen receptor—…